Effect of Sacubitril/Valsartan on circulating catecholamine levels during a 6-month follow-up in heart failure patients. Timeo Danaos et dona ferentes?

We assessed the effect of Sacubitril/Valsartan on circulating catecholamine levels in patients with HF in an observational cohort study. We included 108 consecutive HF patients attending our HF Outpatients Clinic who were eligible to Sacubitril/Valsartan according to the PARADIGM-HF inclusion and ex...

Full description

Saved in:
Bibliographic Details
Published in:Acta Cardiologica 2021-07, Vol.76 (4), p.396-401
Main Authors: Chalikias, George, Kikas, Petros, Thomaidis, Adina, Rigopoulos, Panagiotis, Pistola, Anastasia, Lantzouraki, Asimina, Zisimopoulos, Athanasios, Tziakas, Dimitrios
Format: Article
Language:English
Subjects:
adrenergic system
angiotensin receptor neprilysin inhibitors
catecholamines
epinephrine
norepinephrine
Sacubitril/Valsartan
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We assessed the effect of Sacubitril/Valsartan on circulating catecholamine levels in patients with HF in an observational cohort study. We included 108 consecutive HF patients attending our HF Outpatients Clinic who were eligible to Sacubitril/Valsartan according to the PARADIGM-HF inclusion and exclusion criteria. We furthermore included 58 stable HF patients under optimal medical therapy as a control group. Norepinephrine and epinephrine were measured with immunoradiometric assays at baseline, at 3- and at 6-month time follow-up. Compared to baseline levels there was no change at three months in epinephrine (p = 0.177) or norepinephrine (p = 0.815) concentrations. At 6 months norepinephrine remained unchanged (p = 0.359). However, at 6 months we observed a significant increase in epinephrine levels compared to baseline [66 pg/mL (37−93) vs 38 pg/mL (18-74), p 
ISSN:0001-5385
0373-7934
1784-973X
DOI:10.1080/00015385.2020.1746094